PLK1 in cancer therapy: a comprehensive review of immunomodulatory mechanisms and therapeutic opportunities
PLK1 plays a crucial role in cell cycle regulation and cancer development, and its dysregulation has been implicated in the prognosis of a variety of malignancies. The potential of PLK1 inhibitors as cancer therapeutics has been extensively investigated. However, the underlying biology and mechanism...
Saved in:
| Main Authors: | Weihao Wang, Rui Zhao, Yahui Wang, Liying Pan, Fang Luan, Guobin Fu |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2025-06-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2025.1602752/full |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
The status of p53 affects the efficacy of PLK1 inhibitor BI6727 in prostate cancer cells
by: Wenjing Li, et al.
Published: (2025-07-01) -
MLN0905 effectively kills gemcitabine-resistant pancreatic cancer cells by targeting PLK1
by: Min Lin, et al.
Published: (2025-07-01) -
Expression of FOXM1 and PLK1 in Colorectal Cancer and Their Relationship with Clinicopathological Features and Prognosis
by: Xue HAN, et al.
Published: (2025-07-01) -
Dehydrodiisoeugenol targets the PLK1-p53 axis to inhibit breast cancer cell cycle
by: Lin Li, et al.
Published: (2025-02-01) -
PLK1 inhibition impairs erythroid differentiation
by: Peijun Jia, et al.
Published: (2024-12-01)